Amicus Therapeutics

Home » Amicus Therapeutics

Secondary

Amicus Therapeutics

They are a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.

Symbol

FOLD

Last Closing Price
$15.83

Shares
15,900,000

Effective Date
February 16, 2018

Underwriters
J.P. Morgan, Goldman Sachs, Cowen, Leerink

To view the prospectus for Amicus Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253